An optimized peptide vaccine strategy capable of inducing multivalent CD8$^+$ T cell responses with potent antitumor effects

Hyun-Il Cho$^{1,2}$, Soo-Hyun Jung$^{1,2}$, Hyun-Jung Sohn$^1$, Esteban Celis$^{3,*}$, and Tai-Gyu Kim$^{1,2,4,*}$

$^1$Catholic Hematopoietic Stem Cell Bank; College of Medicine; The Catholic University of Korea; Seoul, Korea; $^2$Cancer Research Institute; College of Medicine; The Catholic University of Korea; Seoul, Korea; $^3$Cancer Immunology; Inflammation and Tolerance Program; Georgia Regents University Cancer Center; Augusta, GA USA; $^4$College of Medicine; The Catholic University of Korea; Seoul, South Korea

Keywords: cancer vaccine, dendritic cells, heterologous prime-boost vaccination, multivalent CD8$^+$ T cells, peptide-based vaccine, tumor immunity

Abbreviations: Abs, antibodies; ACT, adoptive cell transfer; APCs, antigen presenting cells; DC, dendritic cells; IL2Cx, IL2/anti-IL2 Abs complexes; PD-1, programmed cell death-1; poly-IC, polyinosine-polycytidylic acid

Therapeutic cancer vaccines are an attractive alternative to conventional therapies for treating malignant tumors, and successful tumor eradication depends primarily on obtaining high numbers of long-lasting tumor-reactive CD8$^+$ T cells. Dendritic cell (DC)-based vaccines constitute a promising approach for treating cancer, but in most instances low immune responses and suboptimal therapeutic effects are achieved indicating that further optimization is required. We describe here a novel vaccination strategy with peptide-loaded DCs followed by a mixture of synthetic peptides, polyinosine-polycytidylic acid (poly-IC) and anti-CD40 antibodies (TriVax) for improving the immunogenicity and therapeutic efficacy of DC-based vaccines in a melanoma mouse model. TriVax immunization 7–12 d after priming with antigen-loaded DCs generated large numbers of long-lasting multiple antigen-specific CD8$^+$ T cells capable of recognizing tumor cells. These responses were far superior to those generated by homologous immunizations with either TriVax or DCs. CD8$^+$ T cells but not CD4$^+$ T cells or NK cells mediated the therapeutic efficacy of this heterologous prime-boost strategy. Moreover, combinations of this vaccination regimen with programmed cell death-1 (PD-1) blockade or IL2 anti-IL2 antibody complexes led to complete disease eradication and survival enhancement in melanoma-bearing mice. The overall results suggest that similar strategies would be applicable for the design of effective therapeutic vaccination for treating viral diseases and various cancers, which may circumvent current limitations of cell-based cancer vaccines.

Introduction

One goal in cancer immunotherapy is to activate and expand tumor-reactive CD8$^+$ T cells that are capable of recognizing and destroying tumor cells.1,2 Tumor-reactive CD8$^+$ T cells recognize antigens through the engagement of T cell receptors with a cognate peptide-MHC class I complex on tumor cells. It is evident that tumor cells are poorly immunogenic for initiating CD8$^+$ T cell responses because they express insufficient level of antigens, MHC, and costimulatory molecules.3,4 On the other hand, professional antigen presenting cells (APCs) such as dendritic cells (DCs), when loaded with appropriate tumor antigens, have been proven to trigger tumor-reactive CD8$^+$ T cell responses both in vivo and in vitro.5 In view of this, substantial efforts have been made to develop effective immunotherapeutic strategies utilizing tumor antigen-loaded DCs as vaccines to induce tumor-specific immunity.6,7 In spite of their safety and apparent immunogenicity, no clear evidence has been obtained indicating that DC vaccines provide significant protective immunity in cancer patients that is superior to other vaccination strategies. Thus, we believe that there is a clear need for additional strategies to optimize DC-based cancer vaccines to achieve the desired therapeutic benefit.

We previously described a non-infectious, subunit peptide-based vaccine capable of generating robust and long-lasting antigen-specific CD8$^+$ T cell responses effective against established tumors.8,9 This vaccine called TriVax consists of a mixture of a synthetic peptide corresponding to the minimal CD8$^+$ T cell
Results

TriVax booster immunization after priming with peptide-loaded DCs elicits enhanced and long-lasting CD8\(^+\) T cell responses with potent antitumor effects

To assess whether TriVax (peptide mixed with poly-IC and anti-CD40 Abs) would enhance the immune responses generated by DCs vaccination, we compared several combinational prime-boost immunization modes using the minimal heterologous epitope Trp1\(_{1455/9M}\) (TAPDNLGYM), which has a substitution at position 9 M for A to improve MHC-I binding and immunogenicity.\(^{11,12}\) As shown in Fig. 1A, both Trp1\(_{1455/9M}\)-loaded DCs and Trp1\(_{1455/9M}\) TriVax generated 1–2% antigen-specific IFN\(\gamma\) producing CD8\(^+\) T cells in blood 6 d after priming. The numbers of antigen-specific CD8\(^+\) T cells in blood after the prime were comparable, but the effectiveness of spleen CD8\(^+\) T cells to recognize peptide-pulsed cells and B16 cells was somewhat better in mice vaccinated with antigen-loaded DCs (Fig. S1). When homologous or heterologous booster immunizations were administered 7 d after the prime, evident increases in the numbers of antigen specific CD8\(^+\) T cells were observed in all cases (Fig. 1A, B). However, the magnitude and duration of the secondary T cell response was most dramatic in mice that received Trp1\(_{1455/9M}\) TriVax booster immunization after DC priming (more than 8-fold as compared to the homologous DC vaccination). The reverse heterologous immunization, TriVax prime, DC boost did not induce the massive immune response observed with DC prime-TriVax boost. The large CD8\(^+\) T cell responses induced by DCs prime, TriVax boost (DC_TriVax) were capable of persisting for more than 2 months (Fig. 1B and Fig. S2). Notably, the mice that received DC_TriVax immunization had higher number of Trp1\(_{1455}\)-specific CD8\(^+\) effector T cells with lytic functionality (CD107a/b mobilization) and capable of producing IFN\(\gamma\) observed at day 70 post-vaccination (Fig. 1C and Fig. S3). The functional activity of freshly isolated CD8\(^+\) T cells was evident not only against peptide-pulsed APCs but also toward B16 melanoma cells (Fig. 1D). The optimal time interval between prime (Trp1\(_{1455/9M}\)-loaded DCs) and booster (Trp1\(_{1455/9M}\)TriVax) immunizations was observed to be between 7 and 12 d (Fig. 2). On the other hand, a significantly lower CD8\(^+\) T cell response was observed when the booster immunization was given 5 d post-prime and almost no secondary response was observed when the boost was administered 3 d after the prime. Moreover, we observed that both intravenous and subcutaneous routes of DC vaccination (for priming) were highly effective and comparable for the generation of strong antigen-specific CD8\(^+\) T cell responses followed by TriVax booster immunization (Fig. S4). So far these results indicate that TriVax immunization 7–12 d after priming with antigen-loaded DCs, generates large numbers of long-lasting antigen-specific CD8\(^+\) T cells capable of recognizing tumor cells and that these responses are far superior to those generated by homologous immunization with either TriVax or DCs. The data also imply that although DCs are very effective at priming the CD8\(^+\) T cell responses they are quite ineffective at boosting.

Effects of poly-IC and anti-CD40 Abs on booster immunization after priming with peptide-loaded DCs vaccination

Next, we evaluated the role that each of the components of TriVax play in the secondary expansion of antigen-specific CD8\(^+\) T cells, which were induced by the Trp1\(_{1455/9M}\)-loaded DC priming vaccination. TriVax booster vaccine containing all three components (Trp1\(_{1455/9M}\), poly-IC, and anti-CD40 Abs) was significantly superior to the administration of peptide alone, peptide plus poly-IC, or peptide plus anti-CD40 Abs (Fig. 3A, B). Moreover, substitution of the anti-CD40 Abs for other agonistic Abs reactive with different costimulatory molecules (OX40 and 4-1BB), known to enhance the magnitude and quality of T cell responses, was quite not as effective as anti-CD40, and induced responses similar to those observed with peptide plus anti-CD40. Freshly isolated splenic CD8\(^+\) T cells were effective in recognizing peptide-pulsed EL4 targets and B16 melanoma cells (Fig. 3C, D).

Therapeutic effects of DC prime-TriVax boost vaccination against established B16 melanoma

Next, we evaluated whether Trp1\(_{1455/9M}\) DC_TriVax vaccination would offer a therapeutic benefit against 5 d subcutaneously established B16 tumors (3–5 mm diameter). As shown in Fig. 4A, homologous prime-boost Trp1\(_{1455/9M}\) TriVax vaccinations had a moderate therapeutic effect, whereas the heterologous
Trp1_{455/9M} DC_TriVax immunization exhibited a substantially better antitumor effect. In contrast, the other vaccination protocols tested had negligible therapeutic effects, which were comparable to the no vaccine and the two control groups that received an irrelevant peptide (Ova_{55/DC} Ova_{55/TriVax} and a Trp1_{455/9/MTriVax} immunization priming with DCs not pulsed with peptide (DConly_Trp1_{455/9MTriVax}). The therapeutic antitumor effects induced by these vaccines correlated with the levels of antigen-specific T cells observed in blood (Fig. 4B).

Next, we assessed the roles that various immune cell subsets play in the induction of the therapeutic antitumor effects induced by DC_TriVax vaccination. Specifically we studied the participation of CD8\(^+\), CD4\(^+\) T cells, T regulatory cells and NK cells by in vivo depletion of these cell subsets using specific Abs. Elimination of CD8\(^+\) T cells completely abolished the therapeutic benefit of DC_TriVax vaccination, demonstrating that these cells are crucial for the controlling of established tumors (Fig. 4C). Interestingly, CD4\(^+\) T cell elimination substantially enhanced the therapeutic efficacy of DC_TriVax vaccination with increased frequency of antigen-specific CD8\(^+\) T cells (Fig. 4D). The combination of anti-CD4\(^+\) treatment and DC_TriVax vaccination potentiated the expansion of tumor-reactive CD8\(^+\) T cells, by \(\sim 4\)-fold increase compared with non-combined mice (data not shown). On the other hand, anti-CD25 and anti-NK1.1 antibody treatment had no significant effect on either the antitumor effectiveness of DC_TriVax, or the magnitude of antigen-specific CD8\(^+\) T cells.
We previously observed that PD-1 blockade (with anti-PD-L1 Abs) and the use of IL2 in the form of IL2Cx resulted in a remarkably enhanced therapeutic antitumor effect in mice treated with adoptive T cell transfers followed by TriVax. We evaluated here the addition of anti-PD-L1 Abs and IL2Cx to the Trp1455/9MDC_TriVax vaccination strategy. The results shown in Fig. 4E indicate that PD-1 blockade or IL2Cx potentiated the therapeutic efficacy of DC_TriVax. The improved antitumor effects observed in the IL2Cx combination were accompanied by a substantial increase of Trp1455-specific CD8+ T cells (Fig. 4F). On the other hand, although enhanced therapeutic effects were observed with use of PD-1 blockade, no significant increase of antigen-specific CD8+ T cells was observed in comparison to DC_TriVax immunization alone.

Application of DCs prime-TriVax boost vaccination strategy to different epitopes derived from melanosomal antigens

Next, we inquired whether the DC_TriVax strategy could be extended to other MHC-I binding peptides known to function as strong CD8+ T cell epitopes for mouse melanoma. For these experiments, we examined two T cell epitopes derived from the melanosomal antigens, Trp2180 (SVYDFFVWL) and human gp10025 (KVPRNDQWL), which functions as a heteroclitic CD8+ T cell epitope for mouse gp10025 (mgp10025; EGSRNDQWL). The results showed that mgp10025-specific CD8+ T cell response as compared to homologous hgp10025TriVax prime-boost (Fig. 5A, B). Although a homologous prime-boost Trp2180TriVax vaccination generated high levels of antigen-specific CD8+ T cells, the Trp2180DC_TriVax strategy resulted in approximately 2-fold higher number of antigen-specific melanoma reactive CD8+ T cells. Both peptides generated CD8+ T cells capable of recognizing peptide-pulsed targets and B16 melanoma cells (Fig. 5C). A peptide titration curve comparison between these CD8+ T cells revealed that the Trp2180-specific T cells induced by DC_TriVax exhibited an approximately 10-fold higher avidity as compared with T cells generated by homologous prime-boost TriVax immunization (Fig. 5D).

Multi-epitope-loaded DCs priming followed by TriVax booster immunization induces concurrent effective antitumor CD8+ T cell responses

One of the potential hurdles of tumor immunotherapy using single T cell epitope vaccines is the possibility of the selection of tumor escape variants. In view of this, we explored whether priming using DCs loaded with several peptides followed by multipeptide TriVax would generate a concurrent, multivalent CD8+ T cell response. As shown in Fig. 6A, DC_TriVax using a combination of three peptide epitopes (Trp1455/9M, Trp2180, and hgp10025) triggered a substantial simultaneous CD8+ T cell response to all three epitopes, whereas homologous prime-boost TriVax vaccination mostly generated a Trp2180-specific CD8+
The functional activity of purified CD8$^+$ T cells was studied for their ability to recognize various target cells. Notably, CD8$^+$ T cells from DC_TriVax-immunized mice recognized B16 melanoma cells significantly better as compared with CD8$^+$ T cells from homologous prime-boost TriVax-immunized mice (Fig. 6B). Administration of either DCs loaded with three peptides at the same time (3pepMIX) or a mixture of DCs that were pre-loaded with individual peptides did not make
a difference for inducing an effective CD8+ T cell responses after a TriVax boost (data not shown).

Next, we examined the therapeutic efficacy of 3pepMIX-loaded DC_TriVax against established B16 melanoma in comparison with the individual Trp1455/9M-, Trp2180-, or hgp10025DC_TriVax immunizations. As shown in Fig. 6C, administration of homologous prime-boost 3pepMIX-TriVax had a moderate therapeutic effect that was comparable with hgp10025DC_ hgp100 25TriVax. On the other hand, 3pepMIXDC_3pepMIX TriVax resulted in a remarkably superior therapeutic antitumor effect. Administration of Trp1455/9MDC_TriVax and Trp2180DC_TriVax resulted in an equally intermediate antitumor effect. The presence of antitumor CD8+ T cells was evaluated in spleens of tumor-bearing mice that received Trp1455/9M-, Trp2180-, and 3pep-MIXDC_TriVax on day 36. The results shown in Fig. 6D indicate that multivalent CD8+ T cells capable of effectively recognizing B16 tumor cells were present in 3pepMIXDC_TriVax-vaccinated mice, whereas CD8+ T cells from the mice that received Trp2180DC_TriVax and 3pep-MIXDC_TriVax on day 36. The results presented in Fig. 6E indicate that the addition of either IL2Cx or PD-1 blockade increased dramatically the efficacy of 3pepMIXDC_TriVax vaccination, where several complete tumor eradication were now attained. Furthermore, we validated the presence of antigen-
specific CD8+ T cells in tumor-infiltrating lymphocytes (TIL) and splenocytes. Since the tumor size may impact the effectiveness of T cell immunity, 3pepMIXDC_TriVax vaccination regimen was used to treat 7 d established B16 tumors (≈0.5 cm diameter). Under these circumstances, the addition of PD1 blockade and IL2Cx reduced significantly the median tumor growth rate, but no tumor rejections were observed (Fig. S5A).

When the frequency of antigen-specific CD8+ T cells was measured at day 32, Trp2180-specific CD8+ T cells were dominantly present in TIL and splenocytes and the combination using IL2Cx helped to maintain higher numbers of the Trp2180-specific CD8+ T cells as compared with DC_TriVax alone or DC_TriVax/PD1 blockade (Fig. S5B). Notably, less than 5% of Trp2180-specific CD8+ T cells in TIL (≈0.5%) in splenocytes express PD-1, (receptor for PD-L1), indicating that the addition of IL2Cx and PD-1 blockade had no significant effect on the levels of PD-1 expression on antigen-specific T cells (Figs. S5C, D).

**Discussion**

It is evident that the effectiveness of a therapeutic vaccine will depend in great part on its ability to induce high numbers of long-lasting antigen-specific CD8+ T cells with sufficient high avidity to recognize tumor cells. Our findings provide a promising strategy in which one could achieve high levels of tumor-reactive CD8+ T cell responses by combined administration of antigen-loaded DCs followed by a TriVax booster immunization. When compared with two homologous prime-boost vaccinations, the DCs prime-TriVax boost vaccination generated ≈6-fold higher numbers of functional and long-lasting cytotoxic CD8+ T cells, which were capable of recognizing tumor cells translating into significant therapeutic benefit.

![Figure 5](https://www.tandfonline.com/e1043504-7)

**Figure 5.** Application of DC prime-TriVax boost regimen to various melanosomal antigen epitopes. B6 mice (three per group) were vaccinated intravenously with either peptide-loaded DCs or TriVax (prime); 7 d later, the mice received TriVax booster immunization in the same manner as described in Fig. 1, except Trp2180 and human gp10025 (hgp10025) peptides were used instead of Trp1455/9M (DC_TriVax and TriVax_TriVax, respectively). (A) Eight days after the boost, the presence of antigen-specific CD8+ T cell responses in spleen were evaluated by intracellular IFNγ staining after co-culturing with Trp2180 and mouse gp10025 (mgp10025), respectively. Points, the value for each individual mouse; horizontal line, the average value of the group. (B) Total numbers of intracellular IFNγ-positive CD8+ T cells were calculated from the experiment in A. Columns, mean for each group; bars, SD. (C) Freshly isolated CD8+ T cells from pooled splenocytes were evaluated for antigen-induced IFNγ secretion with peptide-pulsed EL4 (EL4/Trp2180 and EL4/mgp10025, respectively), B16 melanoma, and un-pulsed EL4 cells (negative control). Results represent the average number of spots from triplicate wells with SD (bars) of the means. (D) Antigen-dose responses of purified CD8+ T cells isolated from mice immunized with Trp2180 peptide. Results represent the percent T cell response compared to the maximal response (100%) for each T cell line with SD (bars) from triplicate cultures. P values were calculated using unpaired Student t test comparing with homologous prime-boost TriVax-vaccinated group (*, P < 0.05; ***, P < 0.001).
On the other hand, the converse heterologous TriVax prime-DCs boost immunization was inefficient in generating these types of T cell responses, suggesting that DCs are better at priming and TriVax is superior at boosting immune responses. A similar heterologous prime-boost strategy capable of inducing strong CD8+ T cell responses to non-tumor epitopes was described where DC priming was followed by a recombinant *Listeria monocytogenes* boost. Moreover, our results showed that DC-primed antigen-specific CD8+ T cells could be expanded to huge numbers with a TriVax boost administered as early as 5–7 d after the prime (Fig. 2). These results are in line with the DCs prime, *L. monocytogenes* boost approach, indicating that peptide-loaded DCs could rapidly generate early memory CD8+ T cells capable of undergoing vigorous secondary expansions followed by a highly inflammatory booster immunization generated either by an infectious agent (e.g., *L. monocytogenes*) or a non-infectious synthetic vaccine (TriVax). By using antigen-pulsed DCs, naïve CD8+ T cells are first exposed to antigen, costimulation, and appropriate cytokines for activation and formation of primary memory T cells. There is some evidence that pro-inflammatory cytokines during priming can have negative effect on the rate of memory CD8+ T cell formation. In view of this, the reason why TriVax prime-DCs boost and TriVax prime-TriVax boost immunizations were not as effective as DCs prime-TriVax boost regimen could be lack of early memory CD8+ T cells formulation following initial TriVax priming. Nevertheless, it should be mentioned that efficient priming could be obtained for some peptides using TriVax or peptide plus poly-IC. The ability of a peptide to prime immune responses effectively using TriVax appears to be related to intrinsic properties of the peptide such as size, amphipathicity and whether the peptide represents a self-antigen such as the case of melanosomal proteins. Indeed, we observed that TriVax prime TriVax boost using Trp2180 was quite effective in generating preprimary T cell responses (Fig. 5A). Nevertheless, our results show that an advantage of using peptide-pulsed DCs for priming with the Trp2180 epitope was the generation of higher avidity T cells capable of better recognizing B16 tumor cells and ~10-fold lower amounts of peptide MHC complexes (Fig. 5C, D). Although DC-based cellular vaccines have been widely used in multiple clinical studies in cancer patients, in our view the overall therapeutic efficacy remains suboptimal, suggesting that the immune responses these vaccines generate are not sufficiently robust to limit tumor growth. Regarding route of delivery, many options have been tested where each route has positive and negative aspects to consider. In a report by Mullins et al., the subcutaneous injection of antigen-loaded DCs may confer superior immunogenicity than intravenous delivery. Our results indicated that TriVax booster immunization could efficiently expand the primed CD8+ T cells, which were generated by DC delivery regardless administration routes. Nonetheless, route of *ex vivo*-generated DC delivery still remains to be defined for human clinical trials because it would be extremely difficult to achieve intranodal or intralymphatic administration of DCs in mice. Overall, we believe that a vaccination strategy with antigen-loaded DCs in combination with TriVax immunization boost would be a more effective immunotherapy approach.
as compared to DCs vaccines on their own for treating cancer patients.

Recently, numerous reports have shown the efficacy of heterologous prime-boost regimes for generating an increased number of antigen-specific T cells in inducing potent immune response to pathogens, and various cancers.21-23 Although these strategies have emerged as a more effective vaccination approach in selective enrichment of high avidity T cells,25,26 manufacturing of recombinant agents expressing foreign antigens can be time consuming and technically challenging and the use of infectious recombinant agents for booster immunizations generate safety issues. Although the combination of all three components of TriVax was most effective in secondary expansion of primed CD8⁺ T cells, immunization with peptide plus anti-CD40 Abs was also efficient in eliciting secondary CD8⁺ T cell responses (Fig. 3). Moreover, instead of anti-CD40 Abs, the use of costimulatory Abs to 4-1BB or OX40 (together with poly-IC) was also effective (but slightly less than anti-CD40 Abs) in generating potent secondary T cell responses. These results imply that the anti-CD40 Abs play an important part in the effectiveness of TriVax. The CD40/CD40L costimulatory interaction has been proposed to be critical during the prime for the generation of memory CD8⁺ T cells capable of persisting for long time periods.27-29 The rationale for the use of anti-CD40 Abs in the generation of CD8⁺ T cell responses is to provide the strong costimulatory signal to DCs, which is usually supplied by CD40 ligand (CD40L) expressing CD4⁺ T helper cells.27 Our results indicate that CD40 ligation during the boost results in the vast expansion of memory T cells. There are some indications that virus-reactive memory CD8⁺ T cells expand efficiently upon antigen reencounter when DCs receive CD40 ligation by T helper cells or anti-CD40 Abs.30 Our results suggest that direct costimulation to the CD8⁺ T cells via 4-1BB or OX40 can substitute for CD40 crosslinking on DCs to allow efficient CD8⁺ T cell memory expansion (Fig. 3). CD4⁺ helper T cells play an important role when non-inflammatory vaccines such as antigen-loaded DCs, are used during the prime.27 However, we observed that the combination of anti-CD4⁺ Ab treatment and DC_TriVax vaccination in tumor-bearing mice resulted in the highest percentages of tumor-reactive CD8⁺ T cells (Fig. 4D), and a 4-fold overall increase in total antigen-specific CD8⁺ T cells in spleens compared with non-treated mice (data not shown). Moreover, the elimination of CD4⁺ T cells resulted in significantly increased therapeutic benefits (Fig. 4C). In agreement, earlier studies31,32 have also shown that depletion of CD4⁺ T cells enhanced antitumor immunity with strong CD8⁺ T cell responses. One possible mechanism to explain the strong CD8⁺ T cell responses in CD4⁺ T cell-depleted mice could be reduction of CD4⁺/CD25Foxp3 T regulatory (Treg) cells, which constitutes one of the major suppressive mechanisms for antitumor immunity.33,34 However, when anti-CD25 Abs PC-61 were administered to deplete Treg cells,35 no increase in therapeutic benefit of DCs prime-TriVax boost was observed. These results suggest that CD4⁺ T cell depletion may enhance CD8⁺ responses in DCs prime-TriVax boost not only by Treg depletion but also by inducing partial lymphodepletion allowing better access of the antigen-stimulated T cells to homeostatic lymphokines (IL2, IL7 and IL15).

Although DC prime-TriVax boost regimes enhanced the antitumor efficacy, no complete tumor regressions were observed (Fig. 4A, C). We observed that administration of IL2 (as IL2Cx) or PD-1 blockade to DC_TriVax vaccination enhanced the antitumor therapeutic effect (Fig. 4E) to a similar degree as CD4⁺ T cell depletion, but no complete tumor rejections were observed. It has been reported that the type of IL2Cx used in the present studies enhances the proliferation of memory CD8⁺ T cells without expanding CD4⁺ T regulatory cells.36,37 Our results also showed that IL2Cx increased not only the frequency of antigen-specific CD8⁺ T cells but long-term maintenance of the CD8⁺ T cells, achieving higher therapeutic benefits as compared with...
DCs prime-TriVax alone. Interestingly, while additions of anti-PD-L1 Abs resulted in enhancing antitumor effects as compared with DCs alone, the frequency of antigen-specific CD8+ T cells was similar to DCs alone. PD-1 blockade prevents the generation of exhausted T cells leading to enhanced activation and persistence of antigen-specific T cells. Because PD-L1 expression can be upregulated at the tumor site, it is likely that PD-1 blockade prevents exhaustion of tumor infiltrating T cells, enhancing the effect of the function without the need of the increase in overall T cell numbers observed with IL2Cx.

Lastly, our results showed that DCs prime-TriVax boost strategies allow the simultaneous induction of CD8+ T cell responses to multiple epitopes derived from different melanosomal antigens and resulted in evidently enhanced therapeutic benefits as compared to DCs alone using single antigenic peptide (Fig. 6C). Likewise, the combinations of IL2Cx or PD-1 blockade to these regimes resulted in remarkable antitumor effects where the majority of the mice rejected their tumors (Fig. 6E). It recently became clear that multiple immune inhibitory mechanisms are present in tumor site and it appears to be involved to facilitate tumor heterogeneity, which could cause a proportion of tumor cells to decrease the expression of target antigens. Thus, DCs prime-TriVax boost regimes capable of inducing concurrent multivalent CD8+ T cell responses specific to more than one antigen could overcome the potential limited applicability of single peptide-based vaccines. Collectively, we present data indicating that heterologous multi-epitope DCs prime-TriVax boost vaccines are able to induce large numbers of multivalent CD8+ T cells resulting in remarkable therapeutic antitumor benefits, suggesting that this strategy may achieve desired clinical results in cancer patients.

Materials and Methods

Mice and cell lines

C57BL/6 (B6) mice were purchased from Orient Bio and maintained in our animal facilities under pathogen-free conditions. Animal care and experiments were conducted according to our institutional animal care and use committee guidelines. Murine melanoma B16F10, EL4 thymoma, and RMA-S cells were from the American Type Culture Collection. All of the cell lines were cultured as recommended by the provider.

Peptides, antibodies and reagents

Synthetic peptides representing the CD8+ T cell epitopes Trp2180 (SVYDFFVWL), hgp10025 (KVPRNQDWL), mgp10025 (EGSRNQDWL), Trp1455 (TAPDNLGYA), the heteroclitic analog Trp1455/9M (TAPDNGLGY), and Ova25 (KVVRFDKL) were purchased >80% pure from A&K Labs. Monoclonal anti-mouse CD40 (GK1.5), anti-NK1.1 (PK-136), and anti-CD8 (043504-10 Volume 4 Issue 11 OncoImmunology high molecular weight Poly-IC was purchased from Invivogen. Fluorescence-conjugated Abs were from BioXCell.

Immunization

DCs were generated from bone marrow cells cultured for 7 d with 10 ng/mL granulocyte macrophage colony-stimulating factor and 10 ng/mL IL4. For vaccination, mice were immunized intravenously with 2 x 10^6 DCs pulsed with 10 μg/mL peptide (or in some instance Trp1455/9M, Trp2180, and hgp10025 simultaneously) for 18 h. DCs were mixed with 20 μg poly-IC prior to injection. TriVax consists of 150 μg synthetic peptide, 100 μg anti-CD40 Abs, and 50 μg poly-IC, administered as a mixture via the intravenous (tail vein) route. For PD-1 blockade, anti-PD-L1 Abs were administered intraperitoneally (200 μg/dose) on days 0, 2, and 4 after each immunization (prime and boost). IL2Cx were prepared by incubating 2 μg recombinant mouse IL2 with 10 μg anti-mouse IL2 (JES6-5H4) per dose for 18 h at 4°C. IL2Cx were administered intraperitoneally on days 1 and 3 after prime and boost immunizations.

Evaluation of immune responses

For measuring antigen-specific CD8+ T cell responses, peripheral blood samples or splenocytes were incubated with 1 μg/mL peptide and 1 μl/mL GolgiPlug (BD Bioscience) at 37°C. After 6 h, cells were stained for intracellular IFN-γ following the directions provided by vendor (BD Bioscience) using fluorescence-conjugated Abs against MHC class II, CD8a, and IFNγ. Fluorescence was measured using a FACS Calibur flow cytometer (BD Biosciences) and analyzed using FlowJo software. For CD107a/b mobilization shift assay, 2.5 μg/mL of fluorescence-conjugated anti-CD107a and CD107b Abs were added at the beginning of the stimulation period. To evaluate the in vitro T cell tumor recognition, IFNγ EliSpot assays were performed as described previously, using freshly isolated spleen CD8+ T cells (Miltenyi Biotec). Peptide-pulsed or unpulsed EL4 and B16 melanoma cells were used as target cells. For peptide dose curve responses, serial peptide dilutions were incubated with RMA-S cells overnight and freshly purified CD8+ T cells were added for an additional 40 h before harvesting supernatants to measure IFNγ production by ELISA (eBioscience).

Antitumor effects

B6 mice were inoculated subcutaneously with 2 x 10^5 B16 melanoma cells, and 5 d later when tumors measured ~3–5 mm in diameter the first immunization was administered. Seven days later, the mice were given a heterologous or identical booster. In some experiments, mice received IL2Cx and PD-1 blockade as described above. For in vitro depletion of lymphocyte subsets, each mouse received intraperitoneal administrations of 300 μg Abs against mouse NK1.1, CD4, CD8, and CD25 on days -3 and -1 before the first immunization. Depletions were confirmed with blood samples using flow cytometry (data not shown). Tumor growth was monitored every 3–4 d in individual tagged mice by measuring two opposing diameters with a set of calipers.
Mice were euthanized when the tumor area reached >400 mm². Results are presented as the mean tumor size (area in mm²) ± SD for every treatment group at various time points until the termination of the experiment.

Statistical analyses

Statistical significance to assess the numbers of antigen-specific CD8+ T cells was determined by unpaired Student t tests. Tumor sizes between two populations throughout time were analyzed for significance using two-way ANOVA. All analyses and graphs were done using Prism 5.01 software (GraphPad). The results are representative of data obtained from at least two independent experiments.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Funding

This study was supported by a grant of the Korean Health Technology R&D Project (HI12C0718 and HI12C0759), Ministry of Health & Welfare, Republic of Korea (to H-I. Cho) and by NIH grants R01CA136828 and R01CA157303 (to E. Celis).

Supplemental Material

Supplemental data for this article can be accessed on the publisher’s website.

References

1. Dougan M, Dramm G. Immune therapy for cancer. Immunity 2009; 29:83-117; PMID:19007331; http://dx.doi.org/10.1016/j.immuni.2009.02.018

2. Qin Z, Schwartzkopf J, Pradera F, Kammertoens T, Seliger B, Pircher H, Blankenstein T. A critical requirement of interferon-gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res 2003; 63:6095-100; PMID:12874012

3. Melief CJ, Kast WM. Cytotoxic T lymphocyte therapy of cancer and tumor escape mechanisms. Semin Cancer Biol 2002; 13:347-54; PMID:12077156

4. Hozai M, Bovier A, Tuting T. Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer 2013; 13:365-76; PMID:23735576

5. Steinman RM, Nimmer-Pack M, Inaba K. Dendritic cells: antigen presentation, accessory function and clinical relevance. Adv Exp Med Biol 1993; 329:1-9; PMID:8579358; http://dx.doi.org/10.1007/978-1-4615-2986-9_1

6. Vasuaro A, De Blasio S, Peeters DG, de Koning CC, de Vries JM, Figdor CG, Hato SV. Clinical implications of co-inhibitory molecule expression in the tumor microenvironment for DC vaccination: a game of stop and go. Cancer Immunol Immunother 2002; 51(Suppl 1):S63-70; PMID:12053840; http://dx.doi.org/10.1007/s00262-001-0417-7

7. Benencia F, Sprague L, McGinty J, Pate M, Muccioli M. Antigen-directed CD4+ T cell responses to a single heteroclitic epitope determine cancer immunity. J Clin Immunol 2005; 25:809-17; PMID:15247915; http://dx.doi.org/10.1007/s10875-004-4019-x

8. Qin Z, Schwartzkopf J, Pradera F, Kammertoens T, Seliger B, Pircher H, Blankenstein T. A critical requirement of interferon-gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res 2003; 63:6095-100; PMID:12874012

9. Assudani D, Cho HI, DeVito N, Bradley N, Celis E. In vivo expansion, persistence, and function of peptide-pulsed dendritic cells in cancer immunity. J Immunol 2007; 179:593-63; PMID:17579021; http://dx.doi.org/10.4049/jimmunol.179.1.53

10. Luster A, De Vries JI, Schreiber G, Kallinikos L, Arntzen EH, Jacobs JF, Scharenborg NM, van de Rakt MW, de Boer AJ, Crockeet S et al. Route of administration modulates the induction of dendritic cell vaccines against tumor antigens in advanced melanoma patients. Clin Cancer Res 2011; 17:5725-35; PMID:21771874; http://dx.doi.org/10.1158/1078-0432.CCR-11-1261

11. Benderisch M, Lohler T, Dendritic cells in cancer immunotherapy clinical trials: are we making progress? Front Immunol 2014; 4:454; PMID:24379816; http://dx.doi.org/10.3389/fimmu.2013.00454

12. Mullins DW, Sleasley SL, Ream RM, Bullock TN, Fu YX, Engelland VH. Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med 2003; 198:1033-49; PMID:14530375; http://dx.doi.org/10.1084/jem.2003121348

13. Ramshawa IA, Ramsay AJ. The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today 2000; 21:163-5; PMID:10740236; http://dx.doi.org/10.1016/S0167-5699(00)01612-7

14. Lin T, Liang S, Meng F, Han Q, Guo C, Sun L, Chen Y, Liu Z, Yu Z, Xie H et al. Enhanced immunogenicity and antitumor effects with heterologous prime-boost regimen using vaccines based on M7G4-Ag mimotope of gastric cancer. Clin Exp Immunol 2006; 144:319-25; PMID:16634080; http://dx.doi.org/10.1111/j.1365-2249.2006.03605.x

15. Garcia-Hernandez Mde L, Gray A, Hruby B, Kast WM. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate-1 candidate antigen for treating prostate cancer. Cancer Res 2007; 67:1344-51; PMID:17288172; http://dx.doi.org/10.1158/0008-5472.CAN-06-2996

16. Woodland DL. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol 2004; 25:98-101; PMID:15102360; http://dx.doi.org/10.1016/j.it.2003.11.005

17. Elzard MJ, Muhwil AJ, Brock A, Thompson SA, Medvecky CJ, Ramshawa IA. Prime-boost immunization generates a high frequency, high-avidity CD8+ cytotoxic T lymphocyte population. Int Immunol 2002; 14:31-7; PMID:11751749; http://dx.doi.org/10.1093/intimm/14.1.31

18. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998; 393:478-80; PMID:9624004; http://dx.doi.org/10.1038/30996

19. French RR, Taraban VY, Crowther GR, Rowley TF, Gray JC, Johnson PW, Tutt AL, Al-Shamkhi A, Glennie MJ. Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. Blood 2007; 109:4810-5; PMID:17311995; http://dx.doi.org/10.1182/blood-2006-11-057216

20. Hernandez MG, Shen L, Rock KL. CD40-CD40 ligand interaction between dendritic cells and CD8+ T cells is needed to stimulate maximal T cell responses in the absence of CD4 T cell help. J Immunol 2007; 178:2844-52; PMID:17312128; http://dx.doi.org/10.4049/jimmunol.178.5.2844

21. Bedenikovic G, Crouse J, Osenius A. T-cell help dependence of memory CD8 T cell expansion upon vaccinia virus challenge relies on CD40 signaling. Eur J Immunol 2014; 44:115-26; PMID:24108445; http://dx.doi.org/10.1002/eji.201343805

22. den Boer AT, van Mierlo GJ, Fransen MF, Melief CJ, Offringa R, Toes RE. CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T cell responses in tumor-bearing hosts. Cancer Res 2005; 65:6984-9; PMID:16061684; http://dx.doi.org/10.1158/0008-5472.CAN-04-3344

23. Jeng W, Gershon JA, Johnson BD. Depletion of CD4 T cells enhances immunotherapy for neuroblastoma after synergistic HSCT but compromises development of anti-tumor immune memory. Blood 2009; 113:4449-57; PMID:19182203; http://dx.doi.org/10.1182/blood-2008-11-199087

24. Li X, Kostareli E, Suffner J, Garo N, Hammerling GJ. Efficient Treg depletion induces T-cell infiltration and rejection of large tumors. Eur J Immunol 2010; 40:3325-35; PMID:21072887; http://dx.doi.org/10.1002/eji.201041093

25. Klages K, Mayer CT, Lahl K, Loddenkemper C, Teng NC, Ngow SF, Smyth MJ, Hanahm A, Hujan J, www.tandfonline.com
Sparwasser T. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res 2010; 70:7788-99; PMID:20924102; http://dx.doi.org/10.1158/0008-5472.CAN-10-1736
35. Matsushita N, Pilon-Thomas SA, Martin LM, Riker AI. Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J Immunol Methods 2008; 333:167-79; PMID:18295790; http://dx.doi.org/10.1016/j.jim.2008.01.012
36. Boyman O, Kovar M, Rubinstein MP, Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 2006; 311:1924-7; PMID:16484453; http://dx.doi.org/10.1126/science.1122927
37. Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol 2012; 12:180-90; PMID:22343569; http://dx.doi.org/10.1038/nri3156
38. Ha SJ, Mueller SN, Wherry EJ, Barber DL, Aubert RD, Sharpe AH, Freeman GJ, Ahmed R. Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J Exp Med 2008; 205:543-55; PMID:18332181; http://dx.doi.org/10.1084/jem.20071949
39. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012; 24:207-12; PMID:22286695; http://dx.doi.org/10.1016/j.coi.2011.12.009
40. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF. Up-regulation of PD-L1, IDO, and T(reg) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013; 5:200ra116; PMID:23986400; http://dx.doi.org/10.1126/scitranslmed.3006504
41. Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Crot M, Fatho M, Lenszer V, Wolfl T, Hoezel M et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 2012; 490:412-6; PMID:23051752; http://dx.doi.org/10.1038/nature11538